北京
● 中國(guó)原創(chuàng)黑色素瘤 ●
●●●Original melanoma of China●●●
J Clin Oncol（3篇），JAMA Oncol（1篇），Ann Oncol（3篇），Innovation（1篇），Signal Transduct Target Ther（1篇），Clin Cancer Res（3篇），J Immunother Cancer（4篇），Eur J Cancer（6篇）
中國(guó)原創(chuàng)黑色素瘤
Chin J Cancer Res
Chin J Cancer ResA phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）
Eur J Cancer
Eur J CancerA randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients（2011）
J Clin Oncol
J Clin OncolPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification（2011）
Mol Ther
Mol TherA phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma（2012）
Clin Cancer Res（ChiCTR-TRC-11001798）
Clin Cancer ResPhase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma（2013）
Ann Oncol（NCT01028222）
Ann OncolEfficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial（2017）
BMC Cancer（NCT01910181）
BMC CancerVemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study（2018）
Transl Oncol（KEYNOTE 151）
Transl OncolA phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma（KEYNOTE-151）（2019）
J Clin Oncol（NCT03086174）
J Clin OncolAxitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial（2019）
Eur J Cancer（NCT02083354）
Eur J CancerOpen-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma（2020）
Clin Cancer Res（NCT03013101）
Clin Cancer ResSafety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial（2020）
J Immunother Cancer（CTR20160872）
J Immunother CancerTislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）
J Clin Oncol（NCT02023710）
J Clin OncolRandomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma（2021）
J Immunother Cancer（NCT03086174）
J Immunother CancerToripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis（2021）
Front Oncol（NCT02083354）
Front OncolOverall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial（2021）
Eur J Cancer（NCT03454919）
Eur J CancerPalbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway（2021）
Melanoma Res（NCT03422445）
Melanoma ResPhase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy（2022）
J Immunother Cancer（CTR20140631 and CTR20150881）
J Immunother CancerOrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study（2022）
Ann Oncol（NCT03178123）
Ann OncolToripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial（2022）
BMC Cancer（NCT02738489）
BMC CancerSafety, activity and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study（2022）
Clin Cancer Res（NCT04091217）
Clin Cancer ResAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study（2022）
Eur J Cancer（NCT03932253）
Eur J CancerA first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma（2022）
Front Oncol（KEYNOTE 151）
Front OncolPembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study（2022）
Eur J Cancer（NCT03955354）
Eur J CancerApatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial（2023）
BMC Med（NCT03955354）
BMC MedFirst-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations（2023）
BMC Cancer（NCT04749485）
BMC CancerSafety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study（2023）
J Cancer Res Clin Oncol（NCT04749485）
J Cancer Res Clin OncolEfficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China（2023）
JAMA Oncol（CAP 03）
JAMA OncolCamrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma：The CAP 03 phase 2 nonrandomized clinical trial（2023）
Ann Oncol（NCT04180995）
Ann OncolPhase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma（2023）
J Eur Acad Dermatol Venereol（NCT03991975）
J Eur Acad Dermatol VenereolPhase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma（2024）
Innovation（NCT03545971）
InnovationIBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma（2024）
Eur J Cancer（NCT05217303）
Eur J CancerA phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma（2024）
Signal Transduct Target Ther（NCT04197882）
Signal Transduct Target TherNeoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial（2024）
Oncologist（POLARIS-01）
OncologistFive-year follow-up of POLARIS-01 phase II trial: Toripalimab as salvage monotherapy in Chinese patients with advanced melanoma（2024）
Immunotherapy（SAFFRON-103）
ImmunotherapySAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma（2024）
J Immunother Cancer（NCT04727164）
J Immunother CancerToripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial（2024）
整理者
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺(tái)“網(wǎng)易號(hào)”用戶上傳并發(fā)布，本平臺(tái)僅提供信息存儲(chǔ)服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
